Literature DB >> 11398907

Fluoroquinolones: place in ocular therapy.

A Smith1, P M Pennefather, S B Kaye, C A Hart.   

Abstract

The fluoroquinolones have become widely used antibacterial agents in the treatment of ocular infections, with topical, intravitreal and systemic routes of administration being used. In general, fluoroquinolones (such as ciprofloxacin, ofloxacin, lomefloxacin and norfloxacin) have good activity against gram-negative and gram-positive bacteria. Therapeutic concentrations are achieved in the cornea after topical administration so that the fluoroqinolones have largely replaced combination therapy for the treatment of bacterial keratitis. However, a second line agent is needed when resistance is likely, such as in disease caused by streptococcal species. Reversal of resistance to quinolones may not occur with withdrawal of the antibacterial. This stresses the importance of prudent prescribing to reduce the occurrence of resistance to quinolones. When used in therapeutic topical dosages, corneal toxicity does not occur. Similarly, retinal toxicity is not seen when fluoroquinolones are used at therapeutic dosages, systemically or topically. Corneal precipitation occurs, particularly with ciprofloxacin and to a lesser extent norfloxacin, but does not appear to interfere with healing. In the treatment of endophthalmitis there is reasonable penetration of systemic fluoroquinolones into the vitreous but sufficiently high concentrations to reach the minimum inhibitory concentration for 90% of isolates (MIC90) of all important micro-organisms may not be guaranteed. Systemic administration may be useful for prophylaxis after ocular trauma.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11398907     DOI: 10.2165/00003495-200161060-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  74 in total

1.  Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels.

Authors:  R P Kowalski; L M Karenchak; Y J Gordon
Journal:  Cornea       Date:  1998-05       Impact factor: 2.651

2.  Intravitreal penetration of oral ciprofloxacin in humans.

Authors:  F Z el Baba; M D Trousdale; W J Gauderman; D G Wagner; P E Liggett
Journal:  Ophthalmology       Date:  1992-04       Impact factor: 12.079

3.  Antibiotic therapy of bacterial meningitis: lessons we've learned.

Authors:  M A Sande
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

Review 4.  The clinical use of fluoroquinolones for the treatment of mycobacterial diseases.

Authors:  G J Alangaden; S A Lerner
Journal:  Clin Infect Dis       Date:  1997-11       Impact factor: 9.079

5.  Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycin-cefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group.

Authors:  R A Hyndiuk; R A Eiferman; D R Caldwell; G O Rosenwasser; C I Santos; H R Katz; S S Badrinath; M K Reddy; J P Adenis; V Klauss
Journal:  Ophthalmology       Date:  1996-11       Impact factor: 12.079

6.  Susceptibility testing of Propionibacterium acnes comparing agar dilution with E test.

Authors:  M A Smith; P Alperstein; K France; E M Vellozzi; H D Isenberg
Journal:  J Clin Microbiol       Date:  1996-04       Impact factor: 5.948

7.  Efficacy of ofloxacin vs cefazolin and tobramycin in the therapy for bacterial keratitis. Report from the Bacterial Keratitis Study Research Group.

Authors:  T P O'Brien; M G Maguire; N E Fink; E Alfonso; P McDonnell
Journal:  Arch Ophthalmol       Date:  1995-10

8.  Pharmacokinetics of topically applied ciprofloxacin in rabbit tears.

Authors:  L C Green; M C Callegan; L S Engel; Y Shimomura; D W Jasheway; R J O'Callaghan; J M Hill
Journal:  Jpn J Ophthalmol       Date:  1996       Impact factor: 2.447

9.  Multicenter in vitro comparative study of fluoroquinolones against 25,129 gram-positive and gram-negative clinical isolates.

Authors:  B L Prosser; G Beskid
Journal:  Diagn Microbiol Infect Dis       Date:  1995-01       Impact factor: 2.803

10.  Topical 0.3% ciprofloxacin, norfloxacin, and ofloxacin in treatment of bacterial keratitis: a new method for comparative evaluation of ocular drug penetration.

Authors:  J P Diamond; L White; J P Leeming; H Bing Hoh; D L Easty
Journal:  Br J Ophthalmol       Date:  1995-06       Impact factor: 4.638

View more
  39 in total

Review 1.  Pharmaceutical impurities--a mini-review.

Authors:  Jiben Roy
Journal:  AAPS PharmSciTech       Date:  2002       Impact factor: 3.246

2.  Sustained ocular delivery of ciprofloxacin using nanospheres and conventional contact lens materials.

Authors:  Rahul Garhwal; Sally F Shady; Edward J Ellis; Jeanne Y Ellis; Charles D Leahy; Stephen P McCarthy; Kathryn S Crawford; Peter Gaines
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-03-13       Impact factor: 4.799

3.  Penetration of levofloxacin into the anterior chamber (aqueous humour) of the human eye after intravenous administration.

Authors:  E García-Vázquez; J Mensa; M Sarasa; Y López; P D Couchard; D Soy; J R Fontenla
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-02       Impact factor: 3.267

4.  "Effect of Subinhibitory Concentrations of Some Antibiotics and Low Doses of Gamma Radiation on the Cytotoxicity and Expression of Colibactin by an Uropathogenic Escherichia coli isolate".

Authors:  Radwa N Morgan; Hala A Farrag; Mohammad M Aboulwafa; Sarra E Saleh
Journal:  Curr Microbiol       Date:  2021-01-03       Impact factor: 2.188

5.  Gatifloxacin inducing apoptosis of stromal fibroblasts through cross-talk between caspase-dependent extrinsic and intrinsic pathways.

Authors:  Bin Xu; Yun-Long Sui; Ting-Jun Fan
Journal:  Int J Ophthalmol       Date:  2019-10-18       Impact factor: 1.779

6.  Moxifloxacin efficacy and vitreous penetration in a rabbit model of Staphylococcus aureus endophthalmitis and effect on gene expression of leucotoxins and virulence regulator factors.

Authors:  Stéphane Bronner; François Jehl; Jean-Daniel Peter; Marie-Cécile Ploy; Corinne Renault; Pierre Arvis; Henri Monteil; Gilles Prevost
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

7.  Signal Detection Between Fluoroquinolone Use and the Risk of Rhegmatogenous Retinal Detachment: Sequence Symmetry Analysis Using Nationwide South Korean Healthcare Database Between 2004 and 2015.

Authors:  Yeon-Hee Baek; Sang Jun Park; Sohyun Jeong; In-Sun Oh; Han Eol Jeong; Kyu Hyung Park; Ju-Young Shin
Journal:  Clin Drug Investig       Date:  2018-12       Impact factor: 2.859

Review 8.  Pharmacokinetics and pharmacodynamics of antibacterial agents.

Authors:  Matthew E Levison; Julie H Levison
Journal:  Infect Dis Clin North Am       Date:  2009-12       Impact factor: 5.982

9.  A mucoadhesive polymer extracted from tamarind seed improves the intraocular penetration and efficacy of rufloxacin in topical treatment of experimental bacterial keratitis.

Authors:  Emilia Ghelardi; Arianna Tavanti; Paola Davini; Francesco Celandroni; Sara Salvetti; Eva Parisio; Enrico Boldrini; Sonia Senesi; Mario Campa
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

10.  [Intracameral moxifloxacin: a safe option for endophthalmitis prophylaxis? In vitro safety profile for intraocular application].

Authors:  M Kernt; C Hirneiss; A S Neubauer; R G Liegl; K H Eibl; A Wolf; H de Kaspar; M W Ulbig; A Kampik
Journal:  Ophthalmologe       Date:  2010-08       Impact factor: 1.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.